Carisma Therapeutics Inc

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potential to enhance immune receptor signaling PHILADELPHIA , April 22, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the acceptance of two abstracts at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting being held May 7-11, 2024, in Baltimore, MD. "We are excited to present new preclinical data highlighting the potential of our engineered macrophage cell therapies for the treatment of liver and lung fibrosis, both of which represent significant unmet medical needs with limited available therapies for patients," said Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer of Carisma.

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now

Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company's in vivo CAR-M collaboration with Moderna, and research programs including fibrosis Cash and cash equivalents of $77.6 million as of December 31, 2023, combined with a restructuring of operations, including pausing development of CT-1119, expected to fund the Company into the third quarter of 2025 PHILADELPHIA , April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the fourth quarter, and full year ended December 31, 2023, and provided a business update. "Clinical data generated with CT-0508 in Study 101 has shown that CAR-M is well-tolerated, feasible to manufacture and biologically active in HER2 positive solid tumors.

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

PHILADELPHIA , March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024, in San Diego, California. The poster presentation will showcase preclinical data illustrating the advancements made with Carisma's proprietary Engineered Microenvironment Converters (EM-C) platform.

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

PHILADELPHIA , Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6 th at 2:50 pm ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

PHILADELPHIA , Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.

Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Moderna

First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors PHILADELPHIA , Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting First patient expected to be treated in the first half of 2024 PHILADELPHIA , Nov. 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Having received a Study May Proceed notification from the FDA, Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

PHILADELPHIA , Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 at 2:35 pm ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference

Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-mesothelin CAR-Monocyte Presented pre-clinical proof of concept data of in vivo CAR-M, from the Company's collaboration with Moderna, at SITC Cash, cash equivalents and marketable securities of $94.1 million expected to fund company into the first quarter of 2025 PHILADELPHIA, Nov. 9, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates. "During the third quarter, Carisma made several key advancements across our clinical and pre-clinical programs and reported data from both our Phase 1 clinical study of CT-0508 and our pre-clinical work with Moderna developing in vivo CAR-M," said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

- Data demonstrate feasibility, tolerability, and early efficacy of mRNA/LNP in vivo CAR-M therapy in pre-clinical models of metastatic solid tumors - Proof of concept achieved for platform under the Moderna collaboration - "In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy" to be presented Friday, November 3, 2023, at 11:30 am PT PHILADELPHIA , Oct. 31, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna. The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data abstracts highlighting next-generation enhancements to Carisma's cell therapy platform to be shared PHILADELPHIA , Oct. 25, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California. Two posters highlighting next-generation enhancements to Carisma's CAR-M platform, including a custom intronic shRNA approach and data on Engineered Microenvironment Converters (EM-C), will also be presented.

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

VAALCO Energy

Jerash holdings (US) Inc

To clearly set expectations from the get-go, these top stocks under $5 represent extraordinary risks. As either small or even micro-capitalization enterprises, you automatically should assume volatility when entering this arena.

3 Top Under-$5 Stocks for Strong Gains and Positive Outlook

PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at several upcoming investor conferences, including: H.C.

Carisma Therapeutics to Present at Upcoming Investor Conferences

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508   New translational analyses combining group 1 & group 2 continue to support CAR-M mechanism of action, demonstrating a correlation between biomarkers and best overall response PHILADELPHIA , Sept. 1, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will present findings today at the 8th Annual CAR-TCR Summit from its Phase 1 clinical trial of the Company's lead product candidate, CT-0508, a human epidermal growth factor receptor 2 ("HER2") targeted chimeric antigen receptor macrophage ("CAR-M") for the treatment of advanced/metastatic HER2 overexpressing cancers.

Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

PHILADELPHIA , Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023. These conferences include: 8th Annual CAR-TCR Summit Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer, will give a presentation during the summit.

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

The mean of analysts' price targets for Carisma Therapeutics Inc. (CARM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know

Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of the Company's collaboration with Moderna to develop in-vivo targeted CAR-M therapies Cash, cash equivalents and marketable securities of $117.1 million expected to fund company through 2024 PHILADELPHIA , Aug. 10, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2023, and highlighted recent business updates. "In the second quarter, the Carisma team successfully achieved the important clinical milestone of dosing the first patient in the Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA, which represents the next step in our progression of engineering macrophages for the treatment of solid tumors," said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA® PHILADELPHIA , June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in its Phase I clinical trial that will test the safety and tolerability of the Company's lead product candidate, CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) in combination with Merck's anti-PD1 therapy KEYTRUDA® (pembrolizumab) for the treatment of HER2 overexpressing cancers. Pre-clinical data presented at SITC in 2022 demonstrated that the mice that received both therapies had improved tumor control, overall survival, and tumor microenvironment (TME) activation as compared to either treatment alone, indicating synergy and the capacity for CAR-M to sensitize solid tumors to checkpoint blockade.

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

PHILADELPHIA , June 26, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will join the Russell 2000®, Russell 3000® and Russell Microcap® Indexes following the conclusion of the 2023 Russell indexes annual reconstitution, effective upon the U.S. markets open today, June 26, 2023. "We are thrilled to be added to the Russell indexes, which marks another notable milestone following the successful closing of our merger in March," said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes

These new appointments expand the leadership team to support its legal and human resource sectors to ensure compliance and high quality employee experience PHILADELPHIA , June 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma Therapeutics" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates today. Eric Siegel has been appointed General Counsel and Corporate Secretary and Terry Shields has been named Senior Vice President of Human Resources.

Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources

PHILADELPHIA , June 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several investor conferences in June 2023. These investor conferences include: Jefferies Global Healthcare Conference Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.

Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023

PHILADELPHIA , May 30, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023. These conferences include: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Yara Abdou, MD, will present trials in progress poster during the meeting: A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors Saturday, June 3, 2023, at 8:00 am CT Chicago, Illinois 2023 Fierce Biotech Next Gen Virtual Event Michael Klichinsky, Pharm.D.

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Expanded clinical manufacturing capacity through successful technology transfer of CT-0508  Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol "CARM" PHILADELPHIA , May 11, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights. "In the first quarter, we closed our merger with Sesen Bio, Inc., which further strengthened our foundation to advance our pipeline through the end of 2024," said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

PHILADELPHIA , May 8, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 1:00 pm EDT in New York. A live webcast will be available on the Company's Investor Events webpage and you can also register to view the webcast for the JMP Securities Life Sciences Conference here.

News for Carisma Therapeutics Inc Stock (CARM)